Ten-year patterns of women participating in treatment clinical trials for cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

Assessment of PSMA PET/CT derived predictive markers for 177Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

EVEREST-1: Safety and efficacy data of A2B530, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with solid tumors associated with carcinoembryonic antigen (CEA) ...

Gut-associated checkpoint as a prognostic biomarker in metastatic renal cell carcinoma (mRCC): Results from a randomized first-line clinical trial. Zanzalintinib (zanza) + nivolumab (nivo) ± ...

Progression-free survival as a surrogate outcome for overall survival in ovarian cancer maintenance therapy randomized controlled trials.

Prediction of site-specific immune-related adverse events of PD-L1 blockade in advanced non-small cell lung cancer through baseline organ-metastatic landscape: Pooled post-hoc analyses of two ...

Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study. TACE with or without ...

Epidemiology of plasma cell leukemia in the U.S.: Incidence, mortality and survival predictors. Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) ...

Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group We derived disease ...

Immunotherapy has significantly affected cancer treatment and survival rates, accompanied by an increase in immune-related adverse events (irAEs) requiring new management strategies. irAEs can affect ...

Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health Patients age 20 years and older with AGC, who had experienced disease progression ...

In the primary analysis, median overall survival (OS) was not reached for either arm in either population. 3 We report the final OS analysis, updated safety, and exploratory PFS on third-line therapy ...